Madrigal Pharmaceuticals (MDGL) had the highest return in Q4 2022 by a mid-cap US stock, returning 336.6%.

ASSET	QUARTER	% RETURN
Madrigal Pharmaceuticals (MDGL)	Q4 2022	336.6%
Viking Therapeutics (VKTX)	Q4 2022	240.58%
Immunovant (IMVT)	Q4 2022	213.05%
Verona Pharma PLC ADR (VRNA)	Q4 2022	155.68%
IAMGold (IAG)	Q4 2022	130.36%
89bio (ETNB)	Q4 2022	117.61%
RLX Technology (RLX)	Q4 2022	116.97%
Oceaneering International (OII)	Q4 2022	107.72%
F&G Annuities & Life (FG)	Q4 2022	100.1%
Miniso Group Holding (MNSO)	Q4 2022	99.44%
TG Therapeutics (TGTX)	Q4 2022	96.51%
iQIYI (IQ)	Q4 2022	96.3%
Vaxcyte (PCVX)	Q4 2022	95.71%
Kingsoft Cloud Holdings (KC)	Q4 2022	88.67%
Power Solutions International, Inc Common Stock (PSIX)	Q4 2022	76.47%
Transocean (RIG)	Q4 2022	75.38%
Manchester United (MANU)	Q4 2022	75.28%
Melco Resorts & Entertainment (MLCO)	Q4 2022	72.93%
Axsome Therapeutics (AXSM)	Q4 2022	69.33%
Turkcell Iletisim Hizmetleri AS (TKC)	Q4 2022	68.66%
Powell Industries (POWL)	Q4 2022	65.54%
HUTCHMED DRC (HCM)	Q4 2022	65.14%
Tidewater (TDW)	Q4 2022	63.78%
Arcellx (ACLX)	Q4 2022	63.57%
360 DigiTech (QFIN)	Q4 2022	60.39%

Mid-cap stocks are treated as having a market cap between $2B and $10B.